rhIL-2

DRUG3 trials

Sponsors

Assistance Publique - Hôpitaux de Paris, Celularity Incorporated, The First Affiliated Hospital with Nanjing Medical University

Conditions

MDR TBMultiple MyelomaType 1 Diabetes

Phase 1

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

CompletedNCT02955550

Celularity IncorporatedMultiple Myeloma

Start: 2017-01-05End: 2019-06-04Updated: 2020-07-22

Phase 2

Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes

CompletedNCT02411253

Assistance Publique - Hôpitaux de ParisType 1 Diabetes

Start: 2015-06-30End: 2022-11-30Updated: 2023-08-14

Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB

The First Affiliated Hospital with Nanjing Medical UniversityMDR TB

Start: 2009-06-01End: 2020-03-01Target: 500Updated: 2017-03-03

Related Papers

Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial.

2020-03-2017 citations

Immune Monitoring of CD34+ Placental Cell Derived Natural Killer Cell Therapy (PNK-007) in Phase I Study of Multiple Myeloma

Blood2019-11-131 citations

Abstract CT108: A Phase I study of PNK-007, allogeneic, off the shelf NK cell, post autologous transplant in multiple myeloma (NCT02955550)

Cancer Research2019-07-011 citations

Abstract CT108: A Phase I study of PNK-007, allogeneic, off the shelf NK cell, post autologous transplant in multiple myeloma (NCT02955550)

Clinical Trials2019-07-011 citations

Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial

PLoS Medicine2016-10-11134 citations